{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:54:23Z","timestamp":1761490463610,"version":"build-2065373602"},"reference-count":120,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004072","name":"Kiadis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004176","name":"Miltenyi Biotec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004176","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.bbmt.2018.01.008","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T03:31:50Z","timestamp":1515727910000},"page":"895-908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016"],"prefix":"10.1016","volume":"24","author":[{"given":"Monzr M.","family":"Al Malki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yair","family":"Reisner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7376-9393","authenticated-orcid":false,"given":"Suradej","family":"Hongeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Strober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Mavilio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis-Claude","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ephraim J.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8597-3271","authenticated-orcid":false,"given":"Stefan O.","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.01.008_bib0010","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/bmt.2017.34","article-title":"Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report","volume":"52","author":"Passweg","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0015","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2352-3026(15)00028-9","article-title":"One million haemopoietic stem-cell transplants: a retrospective observational study","volume":"2","author":"Gratwohl","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0020","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1200\/JCO.2017.73.7775","article-title":"Haploidentical hematopoietic cell transplantation using post-transplantation cyclophosphamide: does graft source matter?","volume":"35","author":"Devine","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0025","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.128.2.277","article-title":"The induction of graft versus host disease in mice treated with cyclophosphamide","volume":"128","author":"Owens","year":"1968","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/210139a0","article-title":"Production of graft-versus-host disease in the rat and its treatment with cytotoxic agents","volume":"210","author":"Santos","year":"1966","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0035","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/00007890-197104000-00004","article-title":"The effect of cytotoxic drugs on graft-versus-host disease in mice","volume":"11","author":"Owens","year":"1971","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1399-0012.1987.tb00685.x","article-title":"Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation","volume":"1","author":"Santos","year":"1987","journal-title":"Clin Transplant"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0045","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MD.0b013e318210e685","article-title":"High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases","volume":"90","author":"DeZern","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0055","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0060","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0065","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbmt.2009.11.011","article-title":"Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome","volume":"16","author":"Kasamon","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0070","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","article-title":"Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults","volume":"33","author":"Kasamon","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0075","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0080","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0085","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0090","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0095","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0100","doi-asserted-by":"crossref","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2011-01-333070","article-title":"High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia","volume":"118","author":"Leung","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0110","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2008-02-140095","article-title":"A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation","volume":"112","author":"Ciceri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0115","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","article-title":"Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation","volume":"18","author":"Ciurea","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0120","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood-2009-12-234096","article-title":"Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update","volume":"115","author":"Seggewiss","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0125","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1084\/jem.20041522","article-title":"NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer","volume":"200","author":"Smyth","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0130","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1084\/jem.193.6.661","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis","volume":"193","author":"Smyth","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0140","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/sj.leu.2404892","article-title":"Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia","volume":"21","author":"Savani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0145","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0150","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0155","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","article-title":"Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial","volume":"22","author":"Lee","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0160","doi-asserted-by":"crossref","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0165","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/leu.2014.246","article-title":"Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells","volume":"29","author":"Fei","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0170","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1158\/1078-0432.CCR-12-1243","article-title":"Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy","volume":"19","author":"Liu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0175","doi-asserted-by":"crossref","first-page":"e76781","DOI":"10.1371\/journal.pone.0076781","article-title":"Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity","volume":"8","author":"Shah","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0180","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0185","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-1-4939-3684-7_29","article-title":"Regulatory considerations for NK cells used in human immunotherapy applications","volume":"1441","author":"Lee","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0190","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1002\/cncr.30180","article-title":"Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation","volume":"122","author":"Gaballa","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0195","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0200","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jcyt.2016.02.006","article-title":"Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: clinical implications for cancer treatment","volume":"18","author":"Oyer","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0205","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/leu.2015.260","article-title":"CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT","volume":"30","author":"Cichocki","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0210","doi-asserted-by":"crossref","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0215","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/blood-2012-07-441493","article-title":"Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells","volume":"121","author":"Ophir","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0220","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood.V128.22.3345.3345","article-title":"Next generation veto cells for non-myeloablative haploidentical HSCT: combining anti-viral and graft facilitating activity","volume":"128","author":"Bachar Lustig","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0225","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0230","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0235","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cyto.2011.09.028","article-title":"IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization","volume":"56","author":"Han","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0240","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-12-2357","article-title":"Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu\/Fc fusion complex in syngeneic murine models of multiple myeloma","volume":"73","author":"Xu","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0245","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1182\/blood-2011-10-386995","article-title":"Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function","volume":"119","author":"Foley","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0250","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.4049\/jimmunol.141.10.3478","article-title":"Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes","volume":"141","author":"Lanier","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0255","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","article-title":"CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets","volume":"123","author":"Gleason","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0260","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1158\/1078-0432.CCR-13-0505","article-title":"Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition","volume":"19","author":"Wiernik","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0270","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 Trispecific Killer Engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"10.1016\/j.bbmt.2018.01.008_bib0275","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/bmt.2015.87","article-title":"Improved immune recovery after transplantation of TCRalphabeta\/CD19-depleted allografts from haploidentical donors in pediatric patients","volume":"50","author":"Lang","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0280","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/mt.2016.141","article-title":"Reduction of minimal residual disease in pediatric B-lineage acute lymphoblastic leukemia by an Fc-optimized CD19 antibody","volume":"24","author":"Seidel","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0285","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3324\/haematol.2013.100073","article-title":"Pediatric posttransplant relapsed\/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab","volume":"99","author":"Schlegel","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0290","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0295","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0300","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00277-013-1766-5","article-title":"Acute lymphoblastic leukemia in first complete remission: temporal trend of outcomes in studies comparing allogeneic transplant with autologous transplant or chemotherapy","volume":"92","author":"Messori","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0305","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/leu.2010.260","article-title":"A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor","volume":"25","author":"Kako","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0310","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2012-07-445098","article-title":"Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis","volume":"121","author":"Gupta","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0315","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V126.23.796.796","article-title":"Multi-center US intergroup study of intensive chemotherapy plus dasatinib followed by allogeneic stem cell transplant in patients with Philadelphia chromosome positive acute lymphoblastic leukemia younger than 60","volume":"126","author":"Ravandi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0320","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1158\/1078-0432.CCR-15-2335","article-title":"Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0325","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bbmt.2016.11.008","article-title":"Haploidentical transplantation with post-transplantation cyclophosphamide for high-risk acute lymphoblastic leukemia","volume":"23","author":"Srour","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0330","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-017-0480-5","article-title":"Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT","volume":"10","author":"Santoro","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0335","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.bbmt.2013.04.023","article-title":"Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control","volume":"19","author":"Anurathapan","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0340","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","article-title":"Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation","volume":"325","author":"Gahrton","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0345","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0350","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0355","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","article-title":"The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma","volume":"103","author":"Lokhorst","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0360","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bmt.1703652","article-title":"Fludarabine\/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma","volume":"30","author":"Giralt","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0365","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2002-04-1150","article-title":"Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality","volume":"100","author":"Kr\u00f6ger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0370","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2011-02-337329","article-title":"Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0375","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1182\/blood.V128.22.3475.3475","article-title":"Unmanipulated haploidentical allogeneic hematopoietic cell transplantation for multiple myeloma using post transplant cyclophosphamide anti-GVHD prophylaxis","volume":"128","author":"Castagna","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0380","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1084\/jem.20060376","article-title":"An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues","volume":"203","author":"Chakraverty","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0385","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJM200009143431101","article-title":"Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation","volume":"343","author":"Childs","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0390","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.bbmt.2015.12.017","article-title":"Long-term follow-up of allogeneic hematopoietic stem cell transplantation for solid cancer","volume":"22","author":"Omazic","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0395","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(66)91075-0","article-title":"The effect of lymphoid cells from the lymph of specifically immunized sheep on the growth of primary sarcomata in rats","volume":"287","author":"Alexander","year":"1966","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0400","first-page":"141","article-title":"Mechanisms involved in the antileukemic effect of immunocompetent allogeneic lymphoid cell transfer","volume":"32","author":"Ellman","year":"1972","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0405","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/1097-0142(196001\/02)13:1<79::AID-CNCR2820130115>3.0.CO;2-4","article-title":"Spontaneous regression of human melanoma: clinical and experimental studies","volume":"13","author":"Sumner","year":"1960","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0410","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0306-9877(84)90017-3","article-title":"Rationale for a novel immunotherapy of cancer with allogeneic lymphocyte infusion","volume":"15","author":"Kondo","year":"1984","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0415","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0420","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2004.05328.x","article-title":"Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation","volume":"128","author":"Dey","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0425","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bbmt.2008.02.013","article-title":"The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells","volume":"14","author":"Symons","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0430","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/30989","article-title":"A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell","volume":"393","author":"Ridge","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0435","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/ncomms1948","article-title":"The CD4+ T-cell help signal is transmitted from APC to CD8+ T-cells via CD27-CD70 interactions","volume":"3","author":"Feau","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0440","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1182\/blood-2009-11-253336","article-title":"Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype","volume":"115","author":"Ding","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0445","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0450","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0455","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0460","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0465","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1158\/1078-0432.CCR-11-1066","article-title":"PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer","volume":"17","author":"Amir","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0470","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0475","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0480","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0485","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1089\/hum.1998.9.15-2243","article-title":"Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors","volume":"9","author":"Verzeletti","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0490","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"276","author":"Bonini","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0495","doi-asserted-by":"crossref","first-page":"317ra198","DOI":"10.1126\/scitranslmed.aac8265","article-title":"Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory","volume":"7","author":"Oliveira","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0500","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0505","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm.4015","article-title":"Prospects for gene-engineered T cell immunotherapy for solid cancers","volume":"22","author":"Klebanoff","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0510","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0515","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1182\/blood-2014-01-551671","article-title":"Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0520","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1024533031000072045","article-title":"Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Imamura","year":"2003","journal-title":"Hematology"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0525","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0530","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood-2010-08-264085","article-title":"Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation","volume":"117","author":"Moretta","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0535","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40425-016-0159-4","article-title":"Re-discovering NK cell allo-reactivity in the therapy of solid tumors","volume":"4","author":"Castagna","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0540","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/bmt.2014.266","article-title":"B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY","volume":"50","author":"Roberto","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0545","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood-2014-11-608406","article-title":"Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation","volume":"125","author":"Roberto","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0550","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0555","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3324\/haematol.2014.116053","article-title":"Multifunctional human CD56 low CD16 low natural killer cells are the prominent subset in bone marrow of both healthy pediatric donors and leukemic patients","volume":"100","author":"Stabile","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0560","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","article-title":"NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)","volume":"121","author":"Romee","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0565","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2001-12-0353","article-title":"P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells","volume":"100","author":"Guimond","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0570","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1182\/blood-2010-03-273193","article-title":"Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease","volume":"116","author":"Bastien","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0575","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1053\/j.seminoncol.2012.09.004","article-title":"cell depletion for haplotype-mismatched allogeneic stem cell transplantation","volume":"39","author":"Bastien","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0580","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/14653240510027109","article-title":"Elimination of alloreactive T cells using photodynamic therapy","volume":"7","author":"Boum\u00e9dine","year":"2005","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0585","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood.V128.22.1226.1226","article-title":"Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve event-free survival (GRFS) and overall survival in a T-cell depleted haploidentical HSCT: phase 2 trial in patients with AML and ALL","volume":"128","author":"Roy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0590","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1182\/blood.V118.21.3020.3020","article-title":"Reduction in incidence of severe infections by transplantation of high doses of haploidentical T cells selectively depleted of alloreactive units","volume":"118","author":"Roy","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0595","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2012.43.4738","article-title":"Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia","volume":"30","author":"Mr\u00f3zek","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0600","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0605","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2014-11-608539","article-title":"Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation","volume":"125","author":"Cieri","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.008_bib0610","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118300235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118300235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:01:25Z","timestamp":1761058885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118300235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":120,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1083879118300235"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.008","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}